This is a routine governance announcement. Traders should note the AGM date and agenda, but no immediate trading action is warranted based on this filing alone. Monitor for any unexpected developments during the actual meeting.
PHAR drugs
PHAR drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 16 $17.33entry
- T+1 · 7mo ago +0.06%α −1.16% · $17.34
- T+5 · 7mo ago −3.98%α −4.97% · $16.64
- T+20 · 6mo ago −25.16%α −30.97% · $12.97
- T+60 · 4mo ago −20.54%α −27.59% · $13.77
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharming Group N.V. announced the date and agenda for its 2026 Annual General Meeting of Shareholders (AGM). The meeting will include proposals to appoint KPMG N.V. as auditor, amend non-executive director fees, and renew authorizations for share issuance and repurchase. This is a routine corporate governance filing.
Key Facts
- Pharming Group N.V. announced its 2026 Annual General Meeting of Shareholders (AGM) will be held on May 28, 2026.
- The AGM agenda includes appointing KPMG N.V. as external auditor for 2026-2028.
- The agenda includes proposals to amend fees for Non-Executive Directors.
- The agenda includes renewing authorizations for the Board to issue and repurchase shares.
Financial Impact
The filing contains no new financial data. The share issuance and repurchase authorizations are routine renewals.
Risk Factors
- Routine filing with no material financial risk disclosed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001828316-26-000021 |
| Document: 0001828316-26-000021-index-headers.html | 0001828316-26-000021 |
| Document: 0001828316-26-000021-index.html | 0001828316-26-000021 |
| Document: 0001828316-26-000021.txt | 0001828316-26-000021 |
Track record
18 reports on PHAR
9 of 15 bullish or bearish reports moved the stock their way by T+5. Best: +39.00% at T+20 after the Oct 14, 2026 report. 11 of 15 went positive at some point.
Filters
- Nov 6, 202610d ago 6-K Bullish 5/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Nov 6, 202611d ago Press Release Bullish 6/10 Entry $12.29 to $12.60 Now $12.59 +2.44% ▲ +2.52% −0.07% vs SPY
- Oct 27, 202620d ago 6-K Bullish 6/10 No price data
- Oct 27, 202621d ago Press Release Bullish 6/10 Entry $11.87 to $12.93 Now $12.59 +6.07% ▲ +8.93% +10.92% vs SPY
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $10.67 to $11.86 Now $12.59 +17.99% ▲ +11.15% +10.45% vs SPY
- Oct 14, 20264w ago 6-K Bullish 6/10 Entry $9.64 to $9.65 Now $12.59 +30.60% ▲ +0.10% −0.35% vs SPY
- Sep 29, 20266w ago 6-K Bearish 5/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 29, 20267w ago Press Release Bearish 6/10 Entry $10.01 to $9.68 Now $12.59 −25.77% ▲ +3.30% +5.25% vs SPY
- Sep 25, 20267w ago 6-K Bullish 6/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
- Sep 25, 20267w ago Press Release Bullish 5/10 Entry $10.46 to $9.75 Now $12.59 +20.36% ▼ −6.79% −6.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers